

# Mohamed A Kharfan-Dabaja

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1146320/publications.pdf>

Version: 2024-02-01

258  
papers

5,901  
citations

87888

38  
h-index

110387

64  
g-index

268  
all docs

268  
docs citations

268  
times ranked

6526  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e89-e95.	0.4	2
2	Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. <i>Blood</i> , 2022, 139, 1330-1339.	1.4	52
3	Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 48.e1-48.e10.	1.2	18
4	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	5.2	35
5	Comparative study of therapy-related and de novo adult B-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2022, 196, 963-968.	2.5	6
6	Driving Out Chronic Lymphocytic Leukemia With CAR T Cells. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 5-17.	1.2	4
7	Omission of day +11 methotrexate dose and allogeneic hematopoietic cell transplantation outcomes: results of a systematic review/meta-analysis. <i>Bone Marrow Transplantation</i> , 2022, 57, 65-71.	2.4	2
8	A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. <i>Blood Advances</i> , 2022, 6, 259-269.	5.2	5
9	The Inpatient Unit in a Cancer Center. , 2022, , 15-20.		0
10	Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. <i>Hematological Oncology</i> , 2022, 40, 49-57.	1.7	2
11	Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. <i>Blood Advances</i> , 2022, 6, 920-930.	5.2	16
12	Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. <i>JAMA Oncology</i> , 2022, 8, 404.	7.1	32
13	Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?. <i>Radiotherapy and Oncology</i> , 2022, 166, 171-179.	0.6	27
14	Prospect of CAR T-cell therapy in acute myeloid leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 211-220.	4.1	4
15	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 187.e1-187.e10.	1.2	3
16	Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant. <i>British Journal of Haematology</i> , 2022, 197, 212-222.	2.5	6
17	Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience. <i>Leukemia and Lymphoma</i> , 2022, 63, 1363-1368.	1.3	4
18	Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after three or more lines of prior therapy: evidence of durable benefit. <i>Haematologica</i> , 2022, 107, 1214-1217.	3.5	5

#	ARTICLE	IF	CITATIONS
19	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS). Blood Cancer Journal, 2022, 12, 62.	6.2	6
20	Worldwide Network for Blood and Marrow Transplantation Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2022, 28, 455-462.	1.2	2
21	Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e815-e825.	0.4	2
22	Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma. Blood Cancer Journal, 2022, 12, .	6.2	6
23	Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined <scp>CIBMTR</scp>/<scp>CMWP</scp> of &#x201c;EBMT</scp> analysis. British Journal of Haematology, 2022, 198, 785-789.	2.5	2
24	ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after Failure of Chimeric Antigen Receptor T Cell Therapy (CAR-T) Therapy. Transplantation and Cellular Therapy, 2022, 28, 523-529.	1.2	7
25	Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs. Blood Cancer Journal, 2022, 12, .	6.2	1
26	In-field recurrences in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) bridged with radiation prior to CD19 chimeric antigen receptor T-cell therapy (CAR-T).. Journal of Clinical Oncology, 2022, 40, 7556-7556.	1.6	2
27	Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma. Transplantation and Cellular Therapy, 2022, 28, 610-617.	1.2	6
28	Impact of Rituximab and Corticosteroids on Late Cytopenias Post-Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy, 2022, 28, 668.e1-668.e6.	1.2	4
29	Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: A systematic review and meta-analysis. Hematology/ Oncology and Stem Cell Therapy, 2021, 14, 33-40.	0.9	17
30	Intraocular involvement of Mantle cell lymphoma: A case report and literature review. Hematology/ Oncology and Stem Cell Therapy, 2021, 14, 147-152.	0.9	3
31	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. Transplantation and Cellular Therapy, 2021, 27, 68.e1-68.e9.	1.2	15
32	Relapse of Hodgkin lymphoma after autologous hematopoietic cell transplantation: A current management perspective. Hematology/ Oncology and Stem Cell Therapy, 2021, 14, 95-103.	0.9	0
33	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. Cancer, 2021, 127, 82-92.	4.1	15
34	Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation. Transplantation and Cellular Therapy, 2021, 27, 58-66.	1.2	21
35	Systematic Review/Meta-Analysis on Efficacy of Allogeneic Hematopoietic Cell Transplantation in Sickle Cell Disease: An International Effort on Behalf of the Pediatric Diseases Working Party of European Society for Blood and Marrow Transplantation and the Sickle Cell Transplantation International Consortium. Transplantation and Cellular Therapy, 2021, 27, 167.e1-167.e12.	1.2	8
36	Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALL. Transplantation and Cellular Therapy, 2021, 27, 165.e1-165.e11.	1.2	11

#	ARTICLE	IF	CITATIONS
37	C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 141-146.	0.9	5
38	Outcomes of Hepatosplenic T-Cell Lymphoma: The Mayo Clinic Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 106-112.e1.	0.4	9
39	Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 6-20.	1.2	45
40	Efficacy of proteasome inhibitor-based maintenance following autologous transplantation in multiple myeloma: A systematic review and meta-analysis. <i>European Journal of Haematology</i> , 2021, 106, 40-48.	2.2	2
41	A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. <i>Blood Advances</i> , 2021, 5, 1154-1163.	5.2	26
42	Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. <i>Blood Cancer Journal</i> , 2021, 11, 49.	6.2	28
43	Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 267.e1-267.e5.	1.2	6
44	A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients. <i>EClinicalMedicine</i> , 2021, 33, 100787.	7.1	14
45	Efficacy of allogeneic hematopoietic cell transplantation in patients with chronic phase CML resistant or intolerant to tyrosine kinase inhibitors. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.9	2
46	Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 592-601.	2.5	17
47	Impact of hypoalbuminemia on the prognosis of relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel. <i>European Journal of Haematology</i> , 2021, 107, 48-53.	2.2	3
48	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	2.4	6
49	Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2194-2202.	2.4	10
50	Enteropathy-Associated T cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 140-147.	2.3	17
51	Impact of time to relapse and response to salvage therapy on post autologous stem cell transplant outcomes in relapsed or refractory diffuse large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19501-e19501.	1.6	0
52	Diagnosis and treatment of subcutaneous panniculitis-like T-cell lymphoma: A systematic literature review. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.9	7
53	Patient perceptions of palliative care in the process of allogeneic hematopoietic cell transplantation.. <i>Journal of Clinical Oncology</i> , 2021, 39, e24082-e24082.	1.6	0
54	Effect of time to relapse on overall survival (OS) in mantle cell lymphoma (MCL) patients (pts) following frontline high-dose therapy and autologous hematopoietic cell transplantation (autoHCT).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7521-7521.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Salvage therapies in transplant-eligible relapsed classic Hodgkin lymphoma, are novel regimens better?. Journal of Clinical Oncology, 2021, 39, 7530-7530.	1.6	1
56	Progression-free survival at 24 months as a landmark after autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma.. Journal of Clinical Oncology, 2021, 39, 7522-7522.	1.6	3
57	Diffuse large B-cell lymphoma with leukemic involvement.. Journal of Clinical Oncology, 2021, 39, e19552-e19552.	1.6	0
58	Cellular Therapies for Mantle Cell Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 363-370.	1.2	6
59	Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions. International Journal of Hematologic Oncology, 2021, 10, IJH33.	1.6	11
60	Ruxolitinib resistance or intolerance in steroidâ€refractory acute graftâ€versus â€host disease â€ a realâ€world outcomes analysis. British Journal of Haematology, 2021, 195, 429-432.	2.5	6
61	Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. JAMA Oncology, 2021, 7, 993.	7.1	44
62	A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention. Blood Advances, 2021, 5, 2740-2750.	5.2	6
63	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. Transplantation and Cellular Therapy, 2021, 27, 921.e1-921.e10.	1.2	11
64	Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 911.e1-911.e7.	1.2	6
65	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2021, 27, 642-649.	1.2	65
66	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. Bone Marrow Transplantation, 2021, 56, 2911-2921.	2.4	21
67	Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. Transplantation and Cellular Therapy, 2021, 27, 923.e1-923.e12.	1.2	15
68	Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphomaâ€type Richter syndrome. Blood Advances, 2021, 5, 3528-3539.	5.2	24
69	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. Bone Marrow Transplantation, 2021, 56, 3068-3077.	2.4	13
70	American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 720-728.	1.2	7
71	Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISHâ€based algorithm distinguishes prognostic groups and outcomes. Blood Cancer Journal, 2021, 11, 156.	6.2	4
72	Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. British Journal of Haematology, 2021, 195, 757-763.	2.5	5

#	ARTICLE	IF	CITATIONS
73	Predictors and management of relapse to axicabtagene ciloleucel in patients with aggressive B-cell lymphoma. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.9	2
74	Lisocabtagene maraleucel in relapsed or refractory diffuse large B cell lymphoma: What is the evidence?. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.9	5
75	Significance of Degree of HLA Disparity When Using Haploidentical Donors with T-Replete PBSC and Post-Transplantation Cyclophosphamide (PTCy) in Acute Myeloid Leukemia (AML) in First Complete Hematologic Remission (CR1). <i>Blood</i> , 2021, 138, 3910-3910.	1.4	0
76	Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma. <i>Blood</i> , 2021, 138, 1750-1750.	1.4	2
77	Characteristics, Management and Outcomes of Patients with Intravascular Lymphoma: A Mayo Clinic Experience. <i>Blood</i> , 2021, 138, 1452-1452.	1.4	0
78	Unique Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (trALL) Following Therapy for Multiple Myeloma (MM). <i>Blood</i> , 2021, 138, 2285-2285.	1.4	0
79	A Calcineurin Inhibitor Free Graft Versus Host Disease (GVHD) Prophylaxis for Patients Undergoing Matched Related (MRD) and Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplant (Allo-HCT). <i>Blood</i> , 2021, 138, 3893-3893.	1.4	0
80	<i>DDX41</i> Variant of Unknown Significance (VUS) Have Distinct Clinical and Diagnostic Features but Are Associated with Similar Prognosis and Co-Mutation Patterns As Pathogenic <i>DDX41</i>: Analysis of the Mayo Clinic (MC) Myeloid Next-Generation Sequencing (NGS) Cohort. <i>Blood</i> , 2021, 138, 3693-3693.	1.4	2
81	Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy. <i>Blood</i> , 2021, 138, 2527-2527.	1.4	3
82	Cytokine release syndrome and neurologic toxicities associated with chimeric antigen receptor T-cell therapy: A comprehensive review of emerging grading models. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 1-6.	0.9	12
83	What is the role of a second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia?. <i>Bone Marrow Transplantation</i> , 2020, 55, 325-331.	2.4	14
84	Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 76-82.	2.0	26
85	Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. <i>Bone Marrow Transplantation</i> , 2020, 55, 698-707.	2.4	4
86	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 472-479.	2.0	21
87	Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. <i>Cancer</i> , 2020, 126, 5077-5087.	4.1	47
88	Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials. <i>Current Research in Translational Medicine</i> , 2020, 68, 159-170.	1.8	24
89	Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2020, 191, 442-452.	2.5	8
90	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 2811-2820.	1.3	7

#	ARTICLE	IF	CITATIONS
91	Impact of Depression and Anxiety on Opioid Use in Hospitalized Hematopoietic Cell Transplantation Recipients. <i>Psychosomatics</i> , 2020, 61, 363-370.	2.5	1
92	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	5.2	18
93	The risk and prognosis of COVID-19 infection in cancer patients: A systematic review and meta-analysis. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, , .	0.9	97
94	Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenström Macroglobulinemia: A Systematic Review and Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e694-e711.	0.4	13
95	Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant. <i>Blood Advances</i> , 2020, 4, 3435-3442.	5.2	30
96	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2181-2189.	2.0	51
97	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2139-2146.	2.0	14
98	Association Between High-grade Myelodysplastic Syndrome and Cutaneous Langerhans Cell Histiocytosis Suggested by Next-Generation Sequencing. <i>JAMA Dermatology</i> , 2020, 156, 817.	4.1	5
99	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020, 4, 1965-1973.	5.2	63
100	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338.	3.5	23
101	Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. <i>JAMA Oncology</i> , 2020, 6, 1011.	7.1	39
102	Hematopoietic Cell Transplant for Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 621-629.	2.2	12
103	Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1784-1802.	2.0	14
104	Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. <i>Journal of Clinical Oncology</i> , 2020, 38, 1518-1526.	1.6	34
105	The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1137-1143.	2.0	13
106	Fatal Mycobacterium abscessus in a recipient of axicabtagene ciloleucel CAR-T: beware of T cells. <i>Bone Marrow Transplantation</i> , 2020, 55, 1464-1465.	2.4	1
107	CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. <i>Bone Marrow Transplantation</i> , 2020, 55, 1525-1532.	2.4	17
108	Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020, 190, 573-582.	2.5	19

#	ARTICLE	IF	CITATIONS
109	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. <i>Leukemia</i> , 2020, 34, 3338-3347.	7.2	27
110	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with <i>FLT3</i> -internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1507-1516.	3.5	91
111	Outcomes of rituximab+BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. <i>Cancer</i> , 2020, 126, 2279-2287.	4.1	17
112	Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1099-1105.	2.0	7
113	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1459-1468.	2.0	35
114	Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?. <i>International Journal of Particle Therapy</i> , 2020, 7, 13-20.	1.8	3
115	Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR. <i>Blood</i> , 2020, 136, 28-29.	1.4	0
116	Survival Outcomes in Blastic Plasmacytoid Dendritic Cell Neoplasm By First-Line Treatment and Stem Cell Transplant. <i>Blood</i> , 2020, 136, 15-15.	1.4	0
117	Impact of Cell of Origin (COO) on Long Term Outcomes Post Autologous Hematopoietic Cell Transplant in Patients with Relapsed/ Refractory Chemotherapy Sensitive De-Novo Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2020, 136, 42-43.	1.4	0
118	Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: results from a single institution study. <i>Leukemia and Lymphoma</i> , 2019, 60, 309-316.	1.3	8
119	Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia. , 2019, , 185-190.		1
120	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019, 25, 5143-5155.	7.0	10
121	Recognizing Risk Factors Associated With Unplanned 30-Day Readmissions in Hematopoietic Cell Transplantation. <i>JAMA Network Open</i> , 2019, 2, e196463.	5.9	0
122	CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. <i>Leukemia</i> , 2019, 33, 2767-2778.	7.2	47
123	Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis. <i>Cancer</i> , 2019, 125, 4417-4425.	4.1	16
124	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2305-2321.	2.0	132
125	Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cells. <i>American Journal of Hematology</i> , 2019, 94, E245-E247.	4.1	1
126	Efficacy of Allogeneic Hematopoietic Cell Transplantation in Human T Cell Lymphotropic Virus Type 1-Associated Adult T Cell Leukemia/Lymphoma: Results of a Systematic Review/Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1695-1700.	2.0	14



#	ARTICLE	IF	CITATIONS
127	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) – an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). <i>Bone Marrow Transplantation</i> , 2019, 54, 1868-1880.	2.4	86
128	Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2330-2337.	2.0	22
129	CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071984158.	2.5	160
130	Autologous Stem Cell Transplantation in Central Nervous System Lymphoma: A Multicenter Retrospective Series and a Review of the Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e273-e280.	0.4	4
131	Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation. <i>JAMA Oncology</i> , 2019, 5, 715.	7.1	44
132	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	5.2	89
133	&lt;p&gt;Cytokine Release Syndrome: Current Perspectives&lt;/p&gt;. <i>ImmunoTargets and Therapy</i> , 2019, Volume 8, 43-52.	5.8	116
134	Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis. <i>Blood Cancer Journal</i> , 2019, 9, 97.	6.2	11
135	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e76-e85.	2.0	85
136	Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1254-1265.	2.4	47
137	Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis. <i>Bone Marrow Transplantation</i> , 2019, 54, 1094-1106.	2.4	36
138	Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. <i>Journal of Hematology and Oncology</i> , 2019, 12, 6.	17.0	29
139	Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 270-278.	2.0	21
140	A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients with Refractory Large B-Cell Lymphoma (ZUMA-14). <i>Blood</i> , 2019, 134, 4093-4093.	1.4	8
141	Therapeutic Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Allogeneic Hematopoietic Cell Transplantation and Novel Therapies. <i>Clinical Hematology International</i> , 2019, 1, 2.	1.7	8
142	Does Addition of Rituximab (R) to BEAM Conditioning Improve Outcomes of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT)? <i>Blood</i> , 2019, 134, 785-785.	1.4	0
143	Efficacy of Allogeneic Hematopoietic Cell Transplantation (HCT) in Sickle Cell Disease: Results of a Systematic Review/Meta-Analysis. <i>Blood</i> , 2019, 134, 2106-2106.	1.4	0
144	Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Classical Hodgkin Lymphoma (cHL): a Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis. <i>Blood</i> , 2019, 134, 3318-3318.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort. <i>Blood</i> , 2019, 134, 2588-2588.	1.4	0
146	Impact of Anti-CD19 CAR-T Axicabtagene Ciloleucel on Vaccine Titers of DTaP and MMR. <i>Blood</i> , 2019, 134, 5610-5610.	1.4	0
147	Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience. <i>Leukemia Research</i> , 2018, 67, 1-5.	0.8	14
148	Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2018, 53, 1434-1444.	2.4	8
149	Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft-versus-host disease score. <i>British Journal of Haematology</i> , 2018, 180, 854-862.	2.5	9
150	Râ€œCHOP </i> versus </i> doseâ€œadjusted Râ€œEPOCH</i> in frontline management of primary mediastinal Bâ€œcell lymphoma: a multiâ€œcentre analysis. <i>British Journal of Haematology</i> , 2018, 180, 534-544.	2.5	70
151	Haploidentical transplantation as a promising therapy for relapsed hemophagocytic lymphohistiocytosis in an older adult patient. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 96-98.	0.9	5
152	Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 1-12.	0.9	7
153	Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 59-68.	1.3	7
154	Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 400-405.	2.0	5
155	Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e35-e39.	0.4	18
156	Reduced intensity is preferred over myeloablative conditioning allogeneic HCT in chronic lymphocytic leukemia whenever indicated: A systematic review/meta-analysis. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 53-64.	0.9	16
157	<i>In vivo</i> IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2018, 103, 531-539.	3.5	25
158	Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 486-493.	2.0	3
159	Using prognostic models in CLL to personalize approach to clinical care: Are we there yet?. <i>Blood Reviews</i> , 2018, 32, 159-166.	5.7	8
160	Allogeneic haematopoietic cell transplantation for extranodal natural killer/Tâ€œcell lymphoma, nasal type: a <sc>CIBMTR</sc> analysis. <i>British Journal of Haematology</i> , 2018, 182, 916-920.	2.5	59
161	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. <i>Blood Advances</i> , 2018, 2, 933-940.	5.2	27
162	Feasibility and Efficacy of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for HIV-Associated Lymphoma: A Single-Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 548-551.	0.4	2

#	ARTICLE	IF	CITATIONS
163	Allogeneic Hematopoietic Cell Transplantation Is an Effective Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm in First Complete Remission: Systematic Review and Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 703-709.e1.	0.4	29
164	Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse. <i>JAMA Oncology</i> , 2018, 4, 1245.	7.1	97
165	Long-Term Follow up of Front-Line Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide (HiLO trial) for Treatment-Naïve Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 3150-3150.	1.4	0
166	Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) on the Outcomes of Angioimmunoblastic T-Cell Lymphoma (AITL): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. <i>Blood</i> , 2018, 132, 969-969.	1.4	0
167	Impact of Depression or Anxiety on Opioid and Benzodiazepine Use in Hospitalized Hematopoietic Stem Cell Transplantation (HSCT) Recipients. <i>Blood</i> , 2018, 132, 4852-4852.	1.4	0
168	Opiate and Benzodiazepine Use during Hospitalization for Hematopoietic Stem Cell Transplantation (HSCT) Is Associated with Adverse Health Related Outcomes. <i>Blood</i> , 2018, 132, 5873-5873.	1.4	1
169	IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2017, 102, 948-957.	3.5	33
170	Hematopoietic cell transplantation: Training challenges and potential opportunities through networking and integration of modern technologies to the practice setting. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 184-188.	0.9	4
171	Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 117.	17.0	20
172	Improved survival after acute graft-versus-host disease diagnosis in the modern era. <i>Haematologica</i> , 2017, 102, 958-966.	3.5	79
173	Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. <i>British Journal of Haematology</i> , 2017, 179, 781-789.	2.5	56
174	Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1826-1838.	2.0	135
175	TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 753-758.	0.4	18
176	Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 7-13.	0.4	5
177	A Critical Appraisal of Extracorporeal Photopheresis as a Treatment Modality for Acute and Chronic Graft-Versus-Host Disease. <i>Biomedicine</i> , 2017, 5, 60.	3.2	12
178	Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review. <i>Future Oncology</i> , 2016, 12, 2631-2642.	2.4	17
179	Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. <i>British Journal of Haematology</i> , 2016, 174, 235-248.	2.5	115
180	Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front-Line Consolidation or in the Relapsed/Refractory Setting: A Systematic Review/Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 802-814.	2.0	37

#	ARTICLE	IF	CITATIONS
181	Allo-HCT regimens with low toxicity needed in older patients with acute myeloid leukaemia. <i>Lancet Oncology</i> , The, 2016, 17, e1.	10.7	0
182	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2016, 34, 1864-1871.	1.6	61
183	Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. <i>Blood</i> , 2016, 127, 938-947.	1.4	246
184	Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 54-66.	1.7	7
185	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2117-2125.	2.0	87
186	Hematopoietic Cell Transplantation for Richter Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1938-1944.	2.0	11
187	Acute pericarditis and tamponade from Coxsackie B3 in an adult Hematopoietic-Cell-Allograft recipient: A rare but potentially serious complication. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2016, 9, 82-85.	0.9	3
188	Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 3141-3149.	1.6	212
189	Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations. <i>Immunotherapy</i> , 2016, 8, 435-447.	2.0	28
190	Hope for BET inhibition in patients with leukaemia or lymphoma. <i>Lancet Haematology</i> , the, 2016, 3, e157-e158.	4.6	1
191	Clotrimazole troches induce suprathreshold blood levels of sirolimus and tacrolimus in an allogeneic hematopoietic cell-transplant recipient resulting in acute kidney injury. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2016, 9, 157-161.	0.9	16
192	Primary plasmacytoma involving mediastinal lymph nodes: A diagnostic mimicry of primary mediastinal lymphoma. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2016, 9, 26-29.	0.9	7
193	Thymoma with Concomitant Pure Red Cell Aplasia, Goodâ€™s Syndrome and Myasthenia Gravis Responding to Rituximab. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2016, 32, 219-222.	0.6	7
194	Fludarabine and Melphalan Results in Fewer Relapses Compared to Fludarabine and Targeted Busulfan in Patients Receiving Reduced Intensity Conditioning for AML and MDS. <i>Blood</i> , 2016, 128, 3486-3486.	1.4	1
195	Reduced-Intensity or Myeloablative Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: A Side-By-Side Systematic Review/Meta-Analysis. <i>Blood</i> , 2016, 128, 3551-3551.	1.4	0
196	Incidence of Cytomegalovirus (CMV) Reactivation after Autologous Peripheral Blood Stem Cell Transplantation (ASCT) in 324 Patients with Multiple Myeloma and Lymphoma: A Single-Center Study at the American University of Beirut Medical Center (AUBMC). <i>Blood</i> , 2016, 128, 5824-5824.	1.4	0
197	Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease. <i>Haematologica</i> , 2015, 100, 970-977.	3.5	19
198	Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft-versus-Host Disease: Phase I Trial Results. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1074-1082.	2.0	14

#	ARTICLE	IF	CITATIONS
199	Myeloablative Intravenous Pharmacokinetically Targeted Busulfan Plus Fludarabine As Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 335-340.	0.4	8
200	Bortezomib plus dexamethasone results in a late organ response in primary heavy-chain amyloidosis without a hematologic response. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2015, 8, 138-139.	0.9	3
201	Vaccine therapy for cytomegalovirus in the setting of allogeneic hematopoietic cell transplantation. <i>Expert Review of Vaccines</i> , 2015, 14, 341-350.	4.4	14
202	Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2091-2099.	2.0	55
203	Predictors of outcome in reduced intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: summarizing the evidence and highlighting the limitations. <i>Immunotherapy</i> , 2015, 7, 47-56.	2.0	3
204	Guadecitabine for AML and MDS: hype or hope?. <i>Lancet Oncology</i> , The, 2015, 16, 1009-1011.	10.7	5
205	Therapeutic strategies for cytomegalovirus in allogeneic hematopoietic cell transplantation. <i>Immunotherapy</i> , 2015, 7, 1059-1071.	2.0	8
206	Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia after Ibrutinib Discontinuation Outside Clinical Trials: A Single Institution Experience. <i>Blood</i> , 2015, 126, 2945-2945.	1.4	15
207	TP53 and IDH2 Somatic Mutations Are Associated with Poor Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Blood</i> , 2015, 126, 4382-4382.	1.4	1
208	Impact of Splenomegaly in the Presence of Negative PET FDG Avidity on Allogeneic Hematopoietic Cell Transplant Outcomes in Patients with Lymphoid Malignancies. <i>Blood</i> , 2015, 126, 5524-5524.	1.4	0
209	Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T-Cell Lymphomas As Front-Line Consolidation or in the Relapsed/Refractory Setting: A Meta-Analysis. <i>Blood</i> , 2015, 126, 4493-4493.	1.4	0
210	Hypo-Albuminemia at Day+90 after Allogeneic Hematopoietic Cell Transplantation for Lymphoid Malignancies Independently Predicts for Inferior Overall Survival and Higher Non-Relapse Mortality. <i>Blood</i> , 2015, 126, 4407-4407.	1.4	0
211	Pretransplantation 5-Azacitidine in High-Risk Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 776-780.	2.0	19
212	Umbilical cord blood transplantation induces a durable remission in hepatosplenic gamma-delta T cell lymphoma with associated hemophagocytic lymphohistiocytosis. <i>American Journal of Hematology</i> , 2014, 89, 934-935.	4.1	7
213	Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. <i>The Cochrane Library</i> , 2014, 2014, CD010280.	2.8	33
214	A new dawn for gemtuzumab ozogamicin?. <i>Lancet Oncology</i> , The, 2014, 15, 913-914.	10.7	11
215	Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2014, 38, 1165-1172.	0.8	14
216	Allotransplantation for Patients Age <math>\geq 40</math> Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 960-968.	2.0	37

#	ARTICLE	IF	CITATIONS
217	Extracorporeal Photopheresis in Steroid-Refractory Acute or Chronic Graft-versus-Host Disease: Results of a Systematic Review of Prospective Studies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1677-1686.	2.0	95
218	Diagnostic and Therapeutic Advances in Blastic Plasmacytoid Dendritic Cell Neoplasm: A Focus on Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1006-1012.	2.0	75
219	Phase II Study of CD4+-Guided Pentostatin Lymphodepletion and Pharmacokinetically Targeted Busulfan as Conditioning for Hematopoietic Cell Allografting. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1087-1093.	2.0	12
220	Monoclonal Antibodies in Conditioning Regimens for Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1288-1300.	2.0	11
221	Reanalysis of TransVax immunogenicity. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 18.	9.1	9
222	Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies. <i>Immunotherapy</i> , 2013, 5, 457-466.	2.0	41
223	Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. <i>British Journal of Haematology</i> , 2013, 163, 315-325.	2.5	35
224	Conservative Management Vs. Allogeneic Hematopoietic Cell Transplantation For Polycythemia Vera: A Systematic Review and Decision-Analysis. <i>Blood</i> , 2013, 122, 5372-5372.	1.4	1
225	Efficacy Of Novel Agents As Maintenance Therapy For Multiple Myeloma: A Direct and Network Meta-Analysis. <i>Blood</i> , 2013, 122, 1945-1945.	1.4	0
226	A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2012, 97, 1882-1889.	3.5	82
227	Hematopoietic Stem Cell Allografting for Chronic Lymphocytic Leukemia: A Focus on Reduced-Intensity Conditioning Regimens. <i>Cancer Control</i> , 2012, 19, 68-75.	1.8	28
228	A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 290-299.	9.1	224
229	Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2012, 87, 1006-1009.	4.1	60
230	Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission. <i>The Cochrane Library</i> , 2011, , CD008818.	2.8	36
231	Clinical Outcomes of Patients With Plasma Cell Leukemia in the Era of Novel Therapies and Hematopoietic Stem Cell Transplantation Strategies: A Single-Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 507-511.	0.4	37
232	Severe Hypoalbuminemia at Day 90 Predicts Worse Nonrelapse Mortality and Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 384-393.	2.0	20
233	Fludarabine and Pharmacokinetic-Targeted Busulfan before Allografting for Adults with Acute Lymphoid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1505-1511.	2.0	35
234	Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Myeloid Leukemia. <i>Cancer Control</i> , 2011, 18, 237-245.	1.8	33

#	ARTICLE	IF	CITATIONS
235	Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications. <i>International Journal of Hematology</i> , 2011, 93, 206-212.	1.6	15
236	Rituximab for prevention and treatment of graft-versus-host disease. <i>International Journal of Hematology</i> , 2011, 93, 578-585.	1.6	44
237	Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd. <i>Blood</i> , 2011, 118, 323-323.	1.4	1
238	Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PBA±R) Using a Novel Principle of CD4-Guided Immune Suppression. <i>Blood</i> , 2011, 118, 3022-3022.	1.4	0
239	Influenza A/pandemic 2009/H1N1 in the setting of allogeneic hematopoietic cell transplantation: a potentially catastrophic problem in a vulnerable population. <i>International Journal of Hematology</i> , 2010, 91, 124-127.	1.6	39
240	Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. <i>Journal of Hematology and Oncology</i> , 2010, 3, 36.	17.0	47
241	Emerging Role of CD20 Blockade in Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1347-1354.	2.0	18
242	A Randomized Phase II Trial Comparing Tacrolimus and Mycophenolate Mofetil to Tacrolimus and Methotrexate for Acute Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 937-947.	2.0	101
243	Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease. <i>Annals of Transplantation</i> , 2010, 15, 21-9.	0.9	27
244	Current Status of Allogeneic Hematopoietic Stem Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 656-661.	2.0	30
245	Efficacy of Rituximab in the Setting of Steroid-Refractory Chronic Graft-versus-Host Disease: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1005-1013.	2.0	116
246	Phase II Study of Lenalidomide in Combination with Rituximab for Patients with CD5+/CD20+ Hematologic Malignancies Who Relapse or Progress After Rituximab. Interim Analysis.. <i>Blood</i> , 2009, 114, 2376-2376.	1.4	3
247	Apheresis of Hematopoietic Progenitor Cell (HPC) From Allogeneic Donors ≥60 Years of Age.. <i>Blood</i> , 2009, 114, 4226-4226.	1.4	0
248	Salvage Chemotherapy Regimens for Acute Myeloid Leukemia: Is One Better?.. <i>Blood</i> , 2009, 114, 1022-1022.	1.4	0
249	Sirolimus Yields High Response Rates in Hematopoietic Allograft Recipients with Steroid-Refractory Acute Graft-Versus-Host Disease.. <i>Blood</i> , 2009, 114, 2235-2235.	1.4	0
250	Targeted Intravenous Busulfan and Fludarabine Allogeneic Transplantation Conditioning in Acute Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 2290-2290.	1.4	0
251	Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2008, 113, 897-906.	4.1	33
252	Allogeneic Hematopoietic Cell Transplantation for Adult Philadelphia-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 949-958.	2.0	10

#	ARTICLE	IF	CITATIONS
253	Granulocytic sarcoma and chronic lymphocytic leukemia of the gastrointestinal tract after allogeneic hematopoietic cell transplantation mimicking graft-versus-host disease. <i>Leukemia and Lymphoma</i> , 2008, 49, 350-352.	1.3	1
254	Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia: An Evolving Concept. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 373-385.	2.0	23
255	Hematopoietic Cell Transplantation in Acute Promyelocytic Leukemia: A Comprehensive Review. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 997-1004.	2.0	14
256	Systematic review of high dose chemotherapy and autologous haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: what is the published evidence?. <i>British Journal of Haematology</i> , 2007, 139, 234-242.	2.5	8
257	Tandem Versus Single Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials (RCT).. <i>Blood</i> , 2007, 110, 936-936.	1.4	3
258	Granulocytic Sarcoma Presenting with Malignant Anasarca in a Patient with Secondary Acute Myeloid Leukemia. <i>International Journal of Hematology</i> , 2004, 79, 250-252.	1.6	22